Rocket Pharmaceuticals Inc (RCKT) Stock Price, Quote & News

Company Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogeni...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 659 8001

Website: www.rocketpharma.com

Address:

9 Cedarbrook Drive, Cranbury, United States

Risk1123 Aug. 18 at 7:51 PM

$RCKT biggest thing for me is the Danon program and what the FDA says about moving forward with more patients

0 · Reply

DiamondHandsHarold Aug. 18 at 6:00 PM

$RCKT

0 · Reply

Magnificent77 Aug. 18 at 1:06 PM

$RCKT prime buyout looking company??👀

1 · Reply

Prazzclatt Aug. 17 at 8:30 PM

$RCKT The latest Danon safety update was encouraging. All three initial patients cleared the observation period without the major safety issues they were watching for

0 · Reply

DiamondHandsHarold Aug. 17 at 2:10 PM

$RCKT

0 · Reply

Autolus_Freakk Aug. 17 at 1:47 PM

$RCKT any near catalyst on this??

0 · Reply

darntootin Aug. 17 at 1:33 PM

$RCKT Buyout late 2026 early 2027 price 10 billion share price 100 That’s my prediction gl

0 · Reply

buymoremakemore Aug. 14 at 7:45 PM

$RCKT

0 · Reply

Mikey21 Aug. 14 at 4:31 PM

$RCKT bullish!

0 · Reply

stocklover78 Aug. 14 at 2:50 PM

$RCKT

0 · Reply

Rocket Pharmaceuticals price target lowered to $15 from $16 at Wedbush

2026-08-10T20:05:45.000Z - 8 days ago

Rocket Pharmaceuticals reports Q2 EPS $1.08, consensus 35c

Aug 10, 2026, 4:00 PM EDT - 8 days ago

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Rocket Pharmaceuticals Quarterly report: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 9 days ago

Rocket Pharmaceuticals Earnings release: Q2 2026

2026-08-03T11:05:58.000Z - 16 days ago

Rocket announces safety update from three patients treated with RP-A501

Aug 3, 2026, 7:00 AM EDT - 16 days ago

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

2026-06-12T11:05:45.000Z - 2 months ago

Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M

Jun 12, 2026, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 8:10 AM EDT - 2 months ago

Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T15:27:07.000Z - 2 months ago

Rocket Pharmaceuticals price target raised to $10 from $9 at BofA

May 28, 2026, 7:00 AM EDT - 2 months ago

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

May 20, 2026, 9:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Transcript: AGM 2026

2026-05-07T21:49:50.000Z - 3 months ago

Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)

May 7, 2026, 4:00 PM EDT - 3 months ago

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

May 7, 2026, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Rocket Pharmaceuticals Earnings release: Q1 2026

2026-04-28T11:29:11.000Z - 4 months ago

Rocket Pharmaceuticals announces $180M sale of priority review voucher

Apr 28, 2026, 7:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

2026-03-30T10:30:11.000Z - 5 months ago

Rocket Pharmaceuticals price target raised to $9 from $8 at BofA

2026-03-27T19:15:17.000Z - 5 months ago

Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink

2026-03-27T16:13:26.000Z - 5 months ago

PRV reception could net Rocket $100M-$200M, says LifeSci Capital

2026-03-27T16:10:33.000Z - 5 months ago

Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Rocket Pharmaceuticals Transcript: FDA announcement

Mar 27, 2026, 8:30 AM EDT - 5 months ago

Rocket Pharmaceuticals Press release: FDA announcement

Mar 27, 2026, 7:27 AM EDT - 5 months ago

Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder

2026-03-27T11:05:10.000Z - 5 months ago

Rocket Pharmaceuticals announces FDA approval of Kresladi

Mar 27, 2026, 7:00 AM EDT - 5 months ago

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

2026-03-27T00:55:09.000Z - 5 months ago

FDA approves Rocket Pharmaceuticals’ Kresladi in LAD-I

Mar 25, 2026, 8:00 AM EDT - 5 months ago

Rocket Pharmaceuticals Proxy statement: Proxy filing

2026-03-10T21:40:14.000Z - 5 months ago

Rocket Pharmaceuticals offers to sell up to $100M in common stock

Mar 10, 2026, 9:20 AM EDT - 5 months ago

Rocket Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-02T21:21:06.000Z - 6 months ago

Rocket Pharmaceuticals files $400M mixed securities shelf

Mar 2, 2026, 11:10 AM EST - 6 months ago

Rocket Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 7:00 AM EST - 6 months ago

Rocket Pharmaceuticals Registration statement: Registration Filing

2026-03-02T11:54:20.000Z - 6 months ago

Rocket Pharmaceuticals price target raised to $3 from $2 at Goldman Sachs

2026-02-27T15:05:34.000Z - 6 months ago

Rocket Pharmaceuticals price target raised to $10 from $8 at Cantor Fitzgerald

Feb 26, 2026, 4:00 PM EST - 6 months ago

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Feb 26, 2026, 7:00 AM EST - 6 months ago

Rocket Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

Rocket Pharmaceuticals Annual report: Q4 2025

Jan 14, 2026, 2:15 PM EST - 7 months ago

Rocket Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM EST - 8 months ago

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 7:55 AM EST - 9 months ago

Rocket Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 25, 2025, 7:00 AM EST - 9 months ago

Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Nov 6, 2025, 4:00 PM EST - 10 months ago

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rocket Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rocket Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rocket Pharmaceuticals Slides: Corporate Presentation

Oct 14, 2025, 7:00 AM EDT - 11 months ago

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Oct 10, 2025, 4:00 PM EDT - 11 months ago

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 7:11 AM EDT - 11 months ago

Rocket Pharmaceuticals withdraws US application of gene therapy for rare blood disorder

Sep 9, 2025, 9:15 AM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 3:20 PM EDT - 1 year ago

Rocket Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 20, 2025, 11:02 AM EDT - 1 year ago

Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed.

Aug 20, 2025, 7:09 AM EDT - 1 year ago

US FDA lifts clinical hold on Rocket Pharmaceuticals' gene therapy trial

Aug 20, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease

Aug 8, 2025, 2:16 PM EDT - 1 year ago

DEADLINE NEXT WEEK: Berger Montague Advises Rocket Pharmaceuticals (NASDAQ: RCKT) Investors to Contact the Firm Before August 11, 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rocket Pharmaceuticals Quarterly report: Q2 2025

Jul 24, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs

Jul 17, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy

Jul 9, 2025, 5:16 PM EDT - 1 year ago

Berger Montague PC Investigates Rocket Pharmaceuticals (RCKT) Over Safety Disclosures and Stock Drop

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy

Risk1123 Aug. 18 at 7:51 PM

$RCKT biggest thing for me is the Danon program and what the FDA says about moving forward with more patients

0 · Reply

DiamondHandsHarold Aug. 18 at 6:00 PM

$RCKT

0 · Reply

Magnificent77 Aug. 18 at 1:06 PM

$RCKT prime buyout looking company??👀

1 · Reply

Prazzclatt Aug. 17 at 8:30 PM

$RCKT The latest Danon safety update was encouraging. All three initial patients cleared the observation period without the major safety issues they were watching for

0 · Reply

DiamondHandsHarold Aug. 17 at 2:10 PM

$RCKT

0 · Reply

Autolus_Freakk Aug. 17 at 1:47 PM

$RCKT any near catalyst on this??

0 · Reply

darntootin Aug. 17 at 1:33 PM

$RCKT Buyout late 2026 early 2027 price 10 billion share price 100 That’s my prediction gl

0 · Reply

buymoremakemore Aug. 14 at 7:45 PM

$RCKT

0 · Reply

Mikey21 Aug. 14 at 4:31 PM

$RCKT bullish!

0 · Reply

stocklover78 Aug. 14 at 2:50 PM

$RCKT

0 · Reply

DiamondHandsHarold Aug. 14 at 2:39 PM

$RCKT

0 · Reply

wowstepbro Aug. 14 at 2:10 PM

$RCKT KRESLADI approval was ahuge milestone for them. Now the focus can shift toward commercial availability and patient onboarding in Q4

0 · Reply

alotobeer Aug. 14 at 1:53 PM

$RCKT

0 · Reply

Bellz22 Aug. 14 at 1:32 PM

$RCKT

0 · Reply

buymoremakemore Aug. 13 at 9:14 PM

$RCKT Added a bunch today

0 · Reply

Tunes444 Aug. 13 at 1:53 PM

$RCKT Approved drug is not talked about enough

1 · Reply

Risk1123 Aug. 13 at 12:56 PM

$RCKT Wait anyone else feeling this idea?

1 · Reply

darntootin Aug. 12 at 5:23 PM

$RCKT RTW has completed 4 reverse mergers this year alone bringing their next generation of companies to market the last of which happened today I am 100 % convinced they are getting ready to sell RKCT for big Money sometime after a successful meeting with the FDA and a path forward

0 · Reply

Magnificent77 Aug. 12 at 5:01 PM

$RCKT crazy data company with an approved drug is sitting at only a 300 million dollar market cap

0 · Reply

hansfinans Aug. 12 at 6:48 AM

$RCKT Shorts have gone from around 21.9M shares in mid-June to 18.2M, then 16.6M and now 15.5M as of July 31. So almost 30% down in about 6 weeks. Still a lot of shorts out there, but they are clearly reducing. Could be a good sign if the stock finally starts moving up again — less short pressure and potentially some extra buying if they keep covering.

1 · Reply

Wolfietrader Aug. 12 at 12:24 AM

$RCKT why isn’t this taking off?

0 · Reply

Magnificent77 Aug. 11 at 2:40 PM

$RCKT me

1 · Reply

Market Cap	373.24M
Revenue (ttm)	0.00
Net Income (ttm)	-223.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,091,000
Avg Vol	2,232,210
Day's Range	N/A - N/A
Shares Out	109.78M
Stochastic %K	16%
Beta	0.47
Analysts	Sell
Price Target	$8.42